We are live on ! Find out more
GNCA

Genocea Biosciences, Inc.
GNCA

Delisted

GNCA was delisted on the 2nd of June, 2022.

Back to rankings

65 hedge funds and large institutions have $56.4M invested in Genocea Biosciences, Inc. in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

475% more capital invested

Capital invested by funds: $9.81M → $56.4M (+$46.6M)

350% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 6

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

16% more funds holding

Funds holding: 56 → 65 (+9)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
65
Holders Change
+9
Holders Change %
+16.07%
% of All Funds
1.49%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
27
Reduced
6
Closed
8
Calls
$1.57M
Puts
–
Net Calls
+$1.57M
Net Calls Change
+$1.56M

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$26M
2
VC
Vivo Capital
California
+$8.49M
3
BI
BVF Inc
California
+$5.19M
4
BlackRock
BlackRock
New York
+$2.58M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.9M

Top Sellers

Rank Fund Capital Flow
1
NC
Northpointe Capital
Michigan
-$912K
2
AA
AlphaMark Advisors
Kentucky
-$282K
3
VF
Virtu Financial
New York
-$191K
4
Millennium Management
Millennium Management
New York
-$145K
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$83.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
51
IFP Advisors
Florida
$12K – – –
AB
52
Amalgamated Bank
New York
$11K +$10.9K +1,316 New
ProShare Advisors
53
ProShare Advisors
Maryland
$11K +$10.9K +1,317 New
AWA
54
Artemis Wealth Advisors
New York
$9.55K – – –
TRCT
55
Tower Research Capital (TRC)
New York
$5K -$772 -93 -15%
CFA
56
Carroll Financial Associates
North Carolina
$5K – – –
AIP
57
Ameritas Investment Partners
Nebraska
$3K – – –
Federated Hermes
58
Federated Hermes
Pennsylvania
$3K – – –
PWM
59
Perigon Wealth Management
California
$3K – – –
MAM
60
Meeder Asset Management
Ohio
$3K +$1K +121 +58%
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
$1K -$66 -8 -11%
TIM
62
Tortoise Investment Management
New York
$1K +$872 +105 New
NC
63
Northpointe Capital
Michigan
– -$912K -98,329 Closed
Millennium Management
64
Millennium Management
New York
– -$145K -15,650 Closed
MA
65
MYDA Advisors
New York
– -$39K -4,188 Closed
TSS
66
Two Sigma Securities
New York
– -$23K -2,430 Closed
American Century Companies
67
American Century Companies
Missouri
– -$22K -2,371 Closed
UBS Group
68
UBS Group
Switzerland
– -$7K -803 Closed
Manulife (Manufacturers Life Insurance)
69
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$6.04K -727 -96%
Parallax Volatility Advisers
70
Parallax Volatility Advisers
California
– -$5K -546 Closed
1 2
3

GNCA Hedge Fund Activity: Q1 2018 in Review

65 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q1 2018, worth a combined $56.4M — up 475% from $9.81M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new GNCA positions and 8 closed out — a net gain of 9 holders — while 27 added to existing stakes and 6 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $26M. The largest seller was Northpointe Capital, exiting entirely with an estimated $912K sold.

  • 65 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q1 2018, up from 56 in Q4 2017.
  • Funds reported $56.4M of Genocea Biosciences, Inc. stock for Q1 2018, up 475% quarter-over-quarter.
  • 17 funds opened new Genocea Biosciences, Inc. positions in Q1 2018 and 8 closed out, a net change of +9 holders.
  • The largest Genocea Biosciences, Inc. buyer in Q1 2018 was NEA Management Company, an estimated $26M added.
  • The largest Genocea Biosciences, Inc. seller in Q1 2018 was Northpointe Capital, an estimated $912K sold.

Based on aggregated 13F filings for Q1 2018.